New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
09:45 EDTMACK, MACK, MACKMerrimack has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Bob Mulroy on March 7 at 10 am.
News For MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
09:22 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTMACKMerrimack to present updated clinical data from Phase 1 study of MM-141
Merrimack Pharmaceuticals announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors.
06:01 EDTMACKMerrimack price target raised to $16 from $13 at Mizuho
Subscribe for More Information
April 20, 2015
16:07 EDTMACKMerrimack announces final clinical results for MM-302 Phase 1 study
Merrimack Pharmaceuticals announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer. Results from the trial showed that the group of patients treated with 30 mg/m2 or more of MM-302 alone, in combination with trastuzumab or with trastuzumab and cyclophosphamide, had a median progression free survival, or mPFS, of 7.6 months and an overall response rate, or ORR, of 11%. Of note, 25 patients who had not been previously treated with anthracyclines had an mPFS of 11 months and an ORR of 24%. The most frequent adverse events occurring in greater than 20% of the population in this Phase 1 study were constipation, cough, decreased appetite, diarrhea, dyspnea, fatigue, nausea, neutropenia, stomatitis and vomiting. The most common Grade 3/4 adverse event was neutropenia observed in 8 patients. Six out of 69 patients 9% had protocol-defined asymptomatic declines in left ventricular ejection fraction, or LVEF. In 1 of the 6 patients, this was reported as a Grade 1 cardiac failure that was possibly related to study treatment. Merrimack is currently enrolling the HERMIONE study that is designed to support a potential application for accelerated approval in the U.S. and conditional marketing authorization in the E.U. The HERMIONE study is for HER2-positive, metastatic breast cancer patients who are anthracycline-naive and have not been previously treated with pertuzumab and T-DM1-containing regimens.
07:20 EDTMACKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 14, 2015
09:17 EDTMACKMerrimack management to meet with Brean Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use